Resveratrol inhibits VEGF expression of human hepatocellular carcinoma cells through a NF-kappa B-mediated mechanism

Hepato-Gastroenterology

Volumn 57, Issue 102-103, 2010, Pages 1241-1246

  Yu, Hai Bo ^a   Zhang, Hui Feng ^a   Zhang, Xiao ^a   Li, De Yu ^a   Xue, Huan Zhou ^a   Pan, Cheng En ^b   Zhao, Si Hai ^c  

^a HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Angiogenesis; NF kappa B; Resveratrol; Vascular endothelial growth factor

Indexed keywords

CD34 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; RESVERATROL; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MICROVASCULATURE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANTICARCINOGENIC AGENTS; CARCINOMA, HEPATOCELLULAR; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; NF-KAPPA B; RNA, MESSENGER; STILBENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79251543646     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132:2557-2576. (Pubitemid 46890874)
2. Varela M, Sala M, Llovet JM, Bruix J: Treatment of hepatocellular carcinoma: is there an optimal strategy? . Cancer Treat Rev 2003; 29:99-104. (Pubitemid 36519391)
3. Turlin B, Le Quilleuc D, Leroyer P, Brissot P, Deugnier Y, Loréal O: High vascular endothelial growth factor (VEGF) expression in chemically-induced hepatic microcancers in mice. J Hepatol 2002; 37:620-624.
4. Ferguson LR: Role of plant polyphenols in genomic stability. Mutat Res 2001; 475:89-111.
5. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275:218-220.
6. Middleton E Jr, Kandaswami C, Theoharides TC: The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000; 52:673-751.
7. Atten MJ, Attar BM, Milson T, Holian O: Resveratrol-induced inactivation of human gastric adenocarcinoma cells through a protein kinase C-mediated mechanism. Biochem Pharmacol 2001; 62:1423-1432.
8. Murias M, Miksits M, Aust S, Spatzenegger M, Thalhammer T, Szekeres T, et al: Metabolism of resveratrol in breast cancer cell lines: Impact of sulfotransferase 1A1 expression on cell growth inhibition. Cancer Lett 2008; 261:172-182.
9. Woo KJ, Lee TJ, Lee SH, Lee JM, Seo JH, Jeong YJ, et al: Elevated gadd153/chop expression during resveratrol-induced apoptosis in human colon cancer cells. Biochem Pharmacol 2007; 73:68-76.
10. Zoberi I, Bradbury CM, Curry HA, Bisht KS, Goswami PC, Roti Roti JL, et al: Radiosensitizing and antiproliferative effects of resveratrol in two human cervical tumor cell lines. Cancer Lett 2002; 175:165-173.
11. Zunino SJ, Storms DH: Resveratrol-induced apoptosis is enhanced in acute lymphoblastic leukemia cells by modulation of the mitochondrial permeability transition pore. Cancer Lett 2006; 240:123-134.
12. Sen R, Baltimore D: Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986; 47:921-928.
13. Chen F, Castranova V, Shi X: New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol 2001; 159:387-397. (Pubitemid 32751067)
14. Shishodia S, Aggarwal BB: Nuclear factor-kappaB activation: a question of life or death. J Biochem Mol Biol 2002; 35:28-40.
15. Pacifico F, Leonardi A: NF-kappaB in solid tumors. Biochem Pharmacol 2006; 79:1142-52.
16. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107:241-246.
17. Marrogi AJ, Travis WD, Welsh JA, Khan MA, Rahim H, Tazelaar H, et al: Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000; 6:4739-4744.
18. Faith SA, Sweet TJ, Bailey E, Booth T, Docherty JJ: Combined antiviral effects of acyclovir or bromovinyldeoxyuridine and human immunoglobulin in herpes simplex virus-infected mice. Antiviral Res 2006; 72:242-251.
19. Martín AR, Villegas I, Sánchez-Hidalgo M, de la Lastra CA: The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol 2006; 147:873-885.
20. Koga H: Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors? . Cancer 2003; 98:661-667.
21. El-Serag HB, Mason AC, Key C: Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33:62-65.
22. Zhao QT, Yue SQ, Cui Z, Wang Q, Cui X, Zhai HH, et al: Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis. Life Sci 2007; 80:484-492.
23. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60:1306-1311.
24. Inda AM, Andrini LB, García MN, García AL, Fernández Blanco A, Furnus CC, et al: Evaluation of angiogenesis with the expression of VEGF and CD34 in human non-small cell lung cancer. J Exp Clin Cancer Res 2007; 26:375-378.
25. Rini BI, Small EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005; 23:1028-1043.
26. Oak MH, El Bedoui J, Schini-Kerth VB: Antiangiogenic properties of natural polyphenols from red wine and green tea. J Nutr Biochem 2005; 16:1-8. (Pubitemid 40052710)
27. Jakeman LB, Armanini M, Phillips HS, Ferrara N: Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology 1993; 133:848-859.
28. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ: Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001; 20:4188-4197.
29. Woo JH, Lim JH, Kim YH, Suh SI, Min DS, Chang JS, et al: Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene 2004; 23:1845-1853.
30. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143:401-409.